Literature DB >> 9272722

Developmental differences in dopamine synthesis inhibition by (+/-)-7-OH-DPAT.

S L Andersen1, N L Dumont, M H Teicher.   

Abstract

Dopamine synthesis modulation by the D2-family agonist (+/-)-7-OH-DPAT was explored in striatum, accumbens, and prefrontal cortex of 10-40 day old rats using the gamma-butyrolactone (GBL) autoreceptor model. GBL produced an age-dependent increase in dopamine synthesis that was inhibited by (+/-) 7-OH-DPAT (0.1-13.5 mg/kg) at all ages and antagonized by eticlopride in the nucleus accumbens and striatum. The ID50 of (+/-) 7-OH-DPAT increased with age, suggesting decreased autoreceptor sensitivity with maturation. In prefrontal cortex, (+/-) 7-OH-DPAT inhibited synthesis between 10-30 days, with no evidence of autoreceptor function at 40 days. Dopamine synthesis was also inhibited with the D3/D2 agonist quinpirole at 15 days of age in vivo and yielded similar results to those obtained with (+/-) 7-OH-DPAT. Finally, under conditions that result in low D2 receptor affinity, D3 specificity was examined in vitro at 15 days with (+/-) 7-OH-DPAT, which produced comparable (yet more potent) effects to those observed in vivo. These findings illustrate D3 autoreceptor-like activity in ascending dopamine regions and provide further support for transient prefrontal cortex autoreceptor-like function that recedes by puberty.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272722     DOI: 10.1007/pl00005038

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  57 in total

1.  Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats.

Authors:  James D Belluzzi; Alex G Lee; Heather S Oliff; Frances M Leslie
Journal:  Psychopharmacology (Berl)       Date:  2004-01-22       Impact factor: 4.530

2.  Methylphenidate has nonlinear dose effects on cued response inhibition in adults but not adolescents.

Authors:  Nicholas W Simon; Bita Moghaddam
Journal:  Brain Res       Date:  2016-07-16       Impact factor: 3.252

Review 3.  Assessment of adolescent neurotoxicity: rationale and methodological considerations.

Authors:  Linda Patia Spear
Journal:  Neurotoxicol Teratol       Date:  2006-11-23       Impact factor: 3.763

Review 4.  Triadic model of the neurobiology of motivated behavior in adolescence.

Authors:  Monique Ernst; Daniel S Pine; Michael Hardin
Journal:  Psychol Med       Date:  2006-03       Impact factor: 7.723

5.  Early adolescents show enhanced acute cocaine-induced locomotor activity in comparison to late adolescent and adult rats.

Authors:  Kimberly A Badanich; Antoniette M Maldonado; Cheryl L Kirstein
Journal:  Dev Psychobiol       Date:  2008-03       Impact factor: 3.038

Review 6.  Neurobiological processes in adolescent addictive disorders.

Authors:  Ty S Schepis; Bryon Adinoff; Uma Rao
Journal:  Am J Addict       Date:  2008 Jan-Feb

7.  Postnatal manganese exposure does not alter dopamine autoreceptor sensitivity in adult and adolescent male rats.

Authors:  Sanders A McDougall; Alena Mohd-Yusof; Graham J Kaplan; Zuhair I Abdulla; Ryan J Lee; Cynthia A Crawford
Journal:  Eur J Pharmacol       Date:  2013-02-28       Impact factor: 4.432

8.  Reinstatement of cocaine seeking induced by drugs, cues, and stress in adolescent and adult rats.

Authors:  Justin J Anker; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2009-12-02       Impact factor: 4.530

9.  The multifaceted effects of oral administration of methylphenidate in juvenile rats: anxiety, activity, and attention.

Authors:  Ning Zhu; Jeremy Weedon; Diana L Dow-Edwards
Journal:  Eur Neuropsychopharmacol       Date:  2010-01-18       Impact factor: 4.600

10.  Enhanced dopamine D2 autoreceptor function in the adult prefrontal cortex contributes to dopamine hypoactivity following adolescent social stress.

Authors:  Matthew A Weber; Eric T Graack; Jamie L Scholl; Kenneth J Renner; Gina L Forster; Michael J Watt
Journal:  Eur J Neurosci       Date:  2018-07-10       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.